iasodopa 0,3 gbq/ml - konzentrat zur herstellung einer injektionslösung
curium austria gmbh - 6-[*18*f]fluorolevodopa - andere radiodiagnostika z
sogacin 20 mbq/ml injektionslösung
itm medical isotopes gmbh - gallium [*68*ga] edotreotid -
adreview 74 mbq/ml injektionslösung
ge healthcare - iobenguane (i-123) - injektionslösung - 74 mbq/ml - iobenguane (i-123) 74 mbq/ml - iobenguane (123i)
glucogast 1850 mbq/ml injektionslösung
katholieke universiteit te leuven ( ku leuven) - fludeoxyglucose (f-18) - injektionslösung - 1850 mbq/ml - fludeoxyglucose (f-18) 1850 mbq/ml - fludeoxyglucose (18f)
indium (in-111) chloride curium 370 mbq/ml markerzubereitung
curium belgium - indium (in 111) - chlorid - markerzubereitung - 370 mbq/ml - indium (in 111) - chlorid 370 mbq/ml - indium (111in) compounds
mibg i-123 74 mbq/ml injektionslösung
curium belgium - iobenguane (i-123); iobenguane sulfat - injektionslösung - 74 mbq/ml - iobenguane (i-123) 74 mbq/ml; iobenguane sulfat 0.5 mg/ml - iobenguane (123i)
octreoscan
curium netherlands b.v. hr-beiname: mallinckrodt pharmaceuicals, curium, curiumpharma, mallinckrodt medical (3199723) - ((111)in)indium(iii)-chlorid; pentetreotid - kit für ein radioaktives arzneimittel - teil 1 - markerzubereitung; ((111)in)indium(iii)-chlorid (18642) 15 picogramm; teil 2 - pulver zur herstellung einer injektionslösung; pentetreotid (27410) 10 mikrogramm
mibg (i123) injection drn 5379
curium netherlands b.v. hr-beiname: mallinckrodt pharmaceuicals, curium, curiumpharma, mallinckrodt medical (3199723) - iobenguan ((123)i) - injektionslösung - teil 1 - injektionslösung; iobenguan ((123)i) (23268) 2 nanogramm
locametz
novartis europharm limited - gozetotide - radionuklid-bildgebung - diagnostische radiopharmaka - dieses arzneimittel ist nur für diagnostische zwecke bestimmt. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.
efdege 1,0 gbq/ml - injektionslösung
curium austria gmbh - fludeoxyglucose [*18*f] - other diagnostic radiopha